Return to Treatments Available - Pellet Therapy page

 

Testosterone Presentation Bibliography

James C. Roberts MD FACC
11/10/09

 

Physiology and Epidemiology

1.  Testosterone Propionate Therapy in One Hundred Cases of Angina Pectoris.  Lesser, M. A.  New England Heart Association November 26, 1945.

2. Prevalence of Hypogonadism in Men With Coronary Artery Disease.  Pugh, P, et al.  JACC March 19, 2003 Abstract 1050-103.

3. The correlation between testosterone level and coronary artery disease.  Lezha, M, et al.   Abstract P2269, p. 434 (JACC or Circulation abstracts, cannot remember year)

4. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms.  English, K, et al.  European Heart Journal (2000) 21, 890-894.

5. Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Artery Disease in Elderly Men.  Tivestan,A, et al.  JACC 2007;50:1070-76.

6. Low Serum Testosterone and High Serum Estradiol Associate With Lower Extremity Peripheral Artery Disease in Elderly Men.  Tivestan,A, et al.  JACC 2007;50:1070-76.

7. The Coronary Drug Project.  JAMA Nov. 16, 1970 Vol. 214 No. 7 1303-1313.

Used in construction of the presentation but not represented with an individual slide:

Endogenous Sex Hormones and Progression of Carotid Atherosclerosis in Elderly Men
Muller, M, et al.  Circulation 2004;109:2074-2079.

Effect of oestrogens on post exercise electrocardiogram.  Jaffee, M. British Heart Journal, 1977, 38, 1299-1303.

Androgen Deprivation Therapy in Prostate Cancer and Metabolic Risk for Atherosclerosis.  Shanin, S, et al.  Clinical Endocrinology and Metabolism.  Vol. 93, No. 6, pp.  2042-2049.

Low testosterone levels are associated with coronary artery disease in male patients with angina.  Rosano, G, et al.  International Journal of Impotence Research (2007) 19, 176-182.

 

Cardiovascular Risk Factors

1. The Association of Hypotestosteronemia With Coronary Artery Disease in Men.  Phillips, G, et al.  Arterioscler Thromb. 1994;14:701-706.

2. Essential role of post-heparin lipoprotein lipase activity and of plasma testosterone in coronary artery disease.  Breier, C, et al.  The Lancet, June 1, 1985 pp. 1242-01244.

3. Effect of testosterone replacement therapy on lipids and lipoproteins in hypogonadal and elderly men.  Zgliczynski, S, et al.  Atherosclerosis 121 (1996) 35-43.

4. Testosterone Decreased Lipoprotein(a) in Men.  Zmuda, J, et al.  AJC Vol. 77, June 1, 1996 pp. 1244-1247.Lp(a)

5. Natural Androgens Inhibit Male Atherosclerosis. A Study in Castrated, Cholesterol-Fed Rabbits.  Alexandersen, P, et al.  Circ Res 1999;84:813-819.

6. Effect of Testosterone on the Carbohydrate Metabolism in Normal subjects.  Talaat, M, et al.  Arch. Int. Pharmacodyn. 1957, CXI, No. 2 215-226.

7. Testosterone replacement therapy improves insulin resistance, glycemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes.  Kapoor, D, et al.  European Journal of Endocrinology 154 899-906.

8. Regulation of Atrial Natriuretic Peptide, Thromboxane and prostaglandin production by Androgen in Elderly Men with Coronary Heart Disease.  Saizhu, W and Xinxhi, W,  Chinese Medical Sciences Journal December 1993 Vol. 8, No. 4, 207-209.

9. Androgen-Induced Increase in Red-Cell 2,3-Diphosphoglycerate.  Parker, J, et al.  NEJM Aug. 24, 1972 381-383.

10. Endogenous testosterone, fibrinolysis, and coronary heart disease risk in hyperlipidemic men.  Glueck, C, et al.  J Lab Clin Med 1993;122:412-20.

11. Lower androgenicity is associated with higher plasma levels of prothrombotic factors irrespective of age, obesity, body fat distribution, and related metabolic parameters in men.  De Pergola, G, et al.  Metabolism, Vol 46, No 11 (November), 1997: pp 1287-1293.

12. Bio-available testosterone levels fall acutely following myocardial infarction in men:  Association with fibrinolytic factors.  Pugh, P, et al.  Endocrine Research Vol. 28, No. 3, pp. 161-173, 2002.

13. Increase of Blood Fibrinolytic Activity by Testosterone.  Fearnley, G, and Chakrabarti, R.  The Lancet July 21, 1962 128-132.

14. Androgen Treatment of Abdominally Obese Men.  Marin, P, et al.  Obesity Research 1993;1:245-251.

15. The effects of testosterone treatment on body composition and metabolism in middle-aged obese men.  Marin, P, et al.  International Journal of Obesity (1992) 16, 991-997.

16. The effect of testosterone replacement therapy on adipocytokines and C-reactive protein in hypogonadal men with type 2 diabetes.  Kapoor, D, et al.  European Journal of  Endocrinology (2007) 156 595-602.

Used in construction of the presentation but not represented with an individual slide:

The effects of endogenous and exogenous androgens on cardiovascular disease risk factors and progression.  Manolakou, P, et al.  Reproductive Biology and Endocrinology 2009, 7:44 p 1-9.

The Effects of Varying Doses of T on Insulin Sensitivity, Plasma Lipids, Apolipoproteins, and C-Reactive Protein in Healthy YOund Men.  Singh, A, et al.  J Clin endocrinol Metab 87:136-143, 2002.

Effects of androgens on haemostasis.  Winkler, U.  Maturitas 24 (1996) 147-155.

Study of androgen and atherosclerosis in old-age male.  Yang, Y, et al.  Journal of Zhejiang University SCI 2995 6B(9):931-935.


 Immune Function and Inflammation

1. Decreased Testosterone Levels in Men with Rheumatoid Arthritis:  Effect of Low Dose Prednisone Therapy.  Martens, H, et al.  J Rheumatol 1994;21:1427-31.

2. Androgen Replacement Therapy in Male Patients with Rheumatoid Arthritis.  Cutolo, M, et al.  Arthritis and Rheumatism, Vol. 34, No. 1 (January 1991) 1-5.

3. Inverse Relationship between Serum Levels of Interleukin-1b and Testosterone in Men with Stable Coronary artery Disease.  Nettleship, J., et al.  Horm Metab Res 2007;39:366-371.

4. C-Reactive protein levels and ageing male symptoms in hypogonadal men treated with testosterone supplementation.  Giltray, E., et al.  Andrologia 40, 398-400.

5. The Effect of Testosterone Replacement on Endogenous Inflammatory Cytokines and Lipid Profiles in Hypogonadal Men.  Malkin, C, et al.  J Clin Endocrinil Metab 89;331-33318, 2004.

6. Regulation of atherosclerotic plaque growth and stability by testosterone and its receptor via influence of inflammatory reaction.  Li, S, et al.  Vascular Pharmacology 49 (2008) 14-14

7. Testosterone alleviates tumor necrosis factor-alpha-mediated tissue factor pathway inhibitor down regulation via suppression of nuclear factor-kappa B in endothelial cells.  Jin, H, et al.  Asian Journal of Andrology (2009):  266-271.

8. Testosterone suppresses tumour necrosis factor production in whole blood from men with heart failure.  Pugh, P, et al.  Abstract 2746.  Page 498.

9. Androgen-replacement therapy depresses the ex vivo production of inflammatory cytokines by circulating antigen-presenting cells in aging thpe-2 diabetic men with partial androgen deficiency.  Corrales, J, et al.  Journal of Endocrinology (2006) 189, 595-604.

10. The Testicular Effects of Tumor Necrosis Factor.  Mealy, K, et al.  Ann. Surg. April 1990 pp. 470-475.

11. Testosterone Acts Directly on CD4+ T Lymphocytes to Increase Il-10 Production.  Liva, S. and Voskuhl, R.  The Journal of Immunology, 2001, 167:2060-2067.

Used in construction of the presentation but not represented with an individual slide:

 Testosterone as a protective factor against atherosclerosis – immunomodulation and influence upon plaque development and stability.  Malkin, C, et al.  Journal of Endocrinology (2003) 178, 373-380.

The Effects of Gonadotropin Treatment on the Immunological Features of Male Patients with Idiopathic Hypogonadotropic Hypogonadism.  Yesilova, Z, et al.  J Clin Endocrinol Metab 85:68-70, 2000

Testosterone inhibits immunoglobulin production by human peripheral blood peripheral mononuclear cells.  Kanda, N, et al.  Clin Exp Immunol 1996;106:410-415.

Relationship of Testosterone with Inflammatory Cytokines in Men with Coronary Artery Disease.  Pugh, P, et al.  JACC March, 19. 2003. Abstract 1050-102.

Prospective Study of Effect of Androgens on Serum Inflammatory Markers in Men.  Ng, M, et al.  Arterioscler Thromb Vasc. Biol. 2002;22:1136-1141.

Fibrous cap formation of destruction – the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation.  Newby, A, and Zaltsman, A.  Cardiovascular Research 41 (1999) 345-360.

 

Coronary Artery Disease

1. Effects of Testosterone on Coronary Vasomotor Regulation in Men With Coronary Heart Disease.  Webb, C, et al.  Circulation 1999;100:1690-1696.

2. Acute haemodynamic effects of testosterone administration in men with heart failure.  Pugh, P, et al.  Abstract 286. Page 28

3. Low-Dose Transdermal Testosterone Therapy Improves Angina Threshold in Men With Chronic Stable Angina. A Randomized, Double-Blind, Placebo-Controlled Study.  English, K, et al.  Circulation 2000;102:1906-1911.

4. Testosterone replacement in hypogonadal men with angina improves ischemic threshold and quality of life.  Malkin, C, et al. Heart 2004;90:871-876.

5. Effects of chronic testosterone administration on myocardial ischemia, lipid metabolism and insulin resistance in elderly male diabetic patients with coronary artery disease.  Cornoldi, A, et al.  Int. J. of Cardiology in press.

6. Therapeutic effects of an androgenic preparation on myocardial ischemia and cardiac function in 62 elderly male coronary heart disease patients.  Sai-zhu, W, and Xin-chi, W.  Chinese Medical Journal 106(6):415-418, 1993.

Used in construction of the presentation but not represented with an individual slide:

Antianginal and Lipid Lowering Effect of Chronic Oral Androgen Supplementation in Elderly Male Patients with Coronary Heart Disease.  Rosano, G, et al.  JACC February 2001 Abstract 835-4.

Effect of Acute Testosterone on Myocardial Ischemia in Men with Coronary Artery Disease.  Webb, C, et al.  AJC Vol. 83, Feb, 1, 1999, pp. 437-439.

 

Congestive Heart Failure

1. Acute haemodynamic effects of testosterone in men with chronic heart failure.  Pugh, P, et al.  European Heart Journal (2003) 24, 909-915.

2. Anabolic Deficiency in Men With Chronic Heart Failure Prevalence and Detrimental Impact on Survival.  Jankowska, E, et al.  Circulation 2006;114:1829-1837.

3. Reduction in Circulating Testosterone Relates to Exercise Capacity in Men With Chronic Heart Failure.  Jankowska, E, et al.  J Cardiac Fail 2009;15:442-450.

4. Testosterone therapy in men with moderate severity heart failure:  a double-blind randomized placebo controlled trial. Malkin, C, et al.  European Heart Journal (2006) 27, 57-64.

5. Testosterone treatment for men with chronic heart failure. Pugh, P, et al.  Heart 2004;90:446-447.

6. Effect of Long-Acting Testosterone Treatment on Functional Exercise Capacity, Skeletal Muscle Performance, Insulin Resistance, and Baroreflex Sensitivity in Elderly Patients With Chronic Heart Failure.  Caminiti, G, et al.  JACC 2009;54:919-27.

7. Effects of Testosterone on Cytokines and Left Ventricular Remodeling Following Heart Failure.  Zhang, Y, et al.  Cell Physiol Biochem 2007;20:847-852.

 

Non-Cardiovascular Benefits

1. Administration of Testosterone is Associated with a Reduced Susceptibility to Myocardial Ischemia.  Callies, F, et la.  Abstract 2693. Page 2694.  2001 Circulation.

2. Wound healing paper

3. Effect of Testosterone Therapy on QT dispersion in Men With Heart Failure.  Malkin, C, et al.  Am J Cardiol 2003;92:1241-43.

4. Hormonal therapies of prostate cancer that induce androgen deficiency:  the impact of testosterone on the QT interval of the electrocardiogram – a potential unrecognized cardioprotective effect.  Pratt, C, et al.  Abstract P 471, page 65.

5. Reduced Testosterone Levels in Males with Lone Atrial Fibrillation.  Lai, J, et al.  Clin. Cardiol. 32, 1, 43-46(2000).

6. Testosterone Replacement in Older Hypogonadal Men:  A 12-Month Randomized Controlled Trial.  Sih, R, et al.  J Clin endocrinol 82:1661-1667, 1997.

7. Low Bone Mineral Density Predicts Significant Coronary Artery Disease at Cardiac Catheterization.  Tran, H, et al.  JACC Abstracts March 19, 2003 1200-134.

8. Testosterone Therapy in Glucocorticoid-Treated Men.  Reid, I, et al.  Arch Intern Med. 1996;156:1173-1177.

9. Does Hypogonadism Contribute to the Occurrence of a Minimal Trauma Hip Fracture in Elderly Men?  Stanley, H, et al.  J Am Geriatr Soc 39:766-771, 1991.

10. Dietary calcium, sex hormones, and bone mineral density in men.  Kelly, P, eta l.  BMJ Volume 300 26 May 1990 pp. 1361-1364.

11. Osteoporosis in Hypogonadal Men:  Role of Decreased Plasma 1,25-Dihydroxyvitamin D, Calcium Malabsorption, and low Bone Formation.  Francis, R, et al.  Bone, 7, 261-268 (1986).

12. Exogenous Testosterone or Testosterone with Finisteride Increases  bone Mineral Density in Older Men with Low Serum testosterone.  Amory, J, et al.  J Clin Endocrinol Metab 89:  503-510, 2004.

13. Adequacy of androgen replacement influences bone density response of testosterone in androgen-deficient men.  Aminorroaya, A, et al.  European Journal of Endocrinology 152 881-886.

14. Testicular Function in Hypercholesterolemic Male Patients During Prolonged Simvastatin Treatmetn.  Azzarito, C, et al.  Horm. Metab. Res. 28 (1996) 193-198.

15. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression.  Seidman, S, and Rabkin, J.  Journal of Affective Disorders 48 (1998) 157-161.

16. Testosterone supplementation improves spatial and verbal memory in healthy older men.  Cherrier, M, et al.  Neurology 2001;57-88.

Used in construction of the presentation but not represented with an individual slide:

Improvement of the diabetic foot upon testosterone administration to hypogonadal men with peripheral arterial disease.  Report of three cases.  Svetlana, K, et al.  Cardiovascualr Diabetology 2009, 8:19, pp. 106.

Increased Incidence of Diagnosed Depressive Illness in Hypogonadal Older Men.  Shores, M, et al. Arch Gen Psychiatry.  2004;61:162-167.

Prostate and Bladder Health

1. The effect of testosterone therapy on lower urinary tract symptoms/bladder and sexual functions in men with symptomatic late-onset hypogonadism.  Karazindiyanoglu, S, and Cayan, S.  The Aging Male, September 2008; 11)3):  146-149.

2. Combined use of androgen and sildenafil for hypogonadal patients unresponsive to sildenafil alone.  Hwant, T, et al.  International Journal of Impotence Research (2006) 18, 400-404.

3. High Levels Of Circulating Testosterone Are Not Associated With Increased Prostate Cancer Risk:  A Pooled Prospective Study.  Stattin, P, eta l.  Int. J. Cancer:  108, 418-424.

4. Prevalence of Prostate Cancer among Hypogonadal Men with Prostate-Specific Antigen levels of 4.0 ng/dl or Less.  Morgentaler, A, and Rhoden, E.  Urology 68:  1263-1267, 2006.

5. Change in Prostate Specific Antigen Following Androgen Stimulation is an Independent Predictor of Prostate Cancer Diagnosis.  Svatek, R, et al.  The Journal of Urology Vol. 179, 2192-2196, June 2008.

6. Prostate-specific antigen changes and prostate cancer in hypogonadal men treated with testosterone replacement therapy.  Coward, R, et al.  BJUI 103, 1179-1183.

7. Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism.  Marks, L, et al.  JAMA 2006;296:2351-2361.

8. PIN Study - Morgantaler

Used in construction of the presentation but not represented with an individual slide:

Concurrent improvement of the metabolic syndrome and lower urinary tract symptoms upon normalization of the plasma testosterone levels in hypogonadal men.  Haider, A, et al.  First International Journal of Andrologia 41, 7-13, 2009.

Medical Progress:  Risks of Testosterone Replacement Therapy and Recommendations for Monitoring.  Rhoden, E, and Morgentaler, A.  NEJM Vol. 350, No. 5, Jan. 29, 2004, pp. 482-490.

Prostate cancer risk in testosterone-treated men.  Raymond, J.  Journal of Steroid Biochemistry and Molcular Biology 102 (2006) 261-266.

Second Round Results of the Finnish Population-Based Prostate Cancer Screening Trial.  Makinen, T, et al.  Clincial Cancer research Vol. 10, 2231-2236, April 1, 2004.

 

Route of Administration

1. Randomized clinical trial of testosterone replacement therapy in hypogonadal men.  Conway, A, et al.  International Journal of Andrology, 1988, 11, pp. 247-264.

2. Which Testosterone Replacement Therapy?  Cantril, J, et al.  Clinical Endocrinology (1984) 21, 97-107.

3. Testosterone release rate and duration of action of testosterone pellet implants.  Kelleher, S, et al.  Clinical Endocrinology (2004) 60, 420-428.

4. An analysis of testosterone implants for androgen replacement therapy.  Handelsman, D, et al.  Clincial Endocrinology (1997) 47, 311-316.

5. Testosterone Therapy.  Reiter, T.  British Journal of Geriatric Practice June, 1977 pp. 137-140.

Used in construction of the presentation but not represented with an individual slide:

Pharmokinetics and pharmacodynamics of subcutaneous testosterone implants in hypogonadal men.  Jockenhovel, F, et al.  Clinical Endocrinology (1996) 45, 61-71.

Pharmokinetics and Pharmacodynamics of Testosterone pellets in Man.  Handelsman, D, et al.  Journal of Clinical Endocrinology and Metabolism 71:216-222, 1990.

 

General articles/books used in construction of the presentation but not represented with an individual slide:

Androgens and Coronary Artery Disease.  Wu, F, and von Eckardstein, A.  Endocrine Reviews 24(2):183-217.

Biological Actions of Androgens.  Mooradian, A, et al.  Endocrine Reviews Feb. 1987 Vol. 8. Pp. 1-24.

Androgen Deficiency and Aging in Men.  Swerdloff, R, et al.  Wst J Med 1993; 159:579-585.Effects of Testosterone Supplementation in the Aging Male.  Tenover, J. Journal of Clicical Endocrinology and Metabolism 1992 Vol. 75No. 4.  Pp. 1092-1097.

Testosterone Replacement Therapy.  Velazquez, E, and Arate, G.  Archives of Andrologyy 41:79-90 (1998) Testosterone Treatment of Cardiovascular Diseases  Moeller, J, and Einfelt, H.  Springer-Verlag Berlin Heidelberg New York Tokoyo 1984